| Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial.Dig Liver Dis | PMID 39562215无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease.Alzheimers Dement | PMID 39575854PMC11848419 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: A randomized trial.Epilepsia | PMID 39576191PMC11827717 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.Clin Genitourin Cancer | PMID 39579409无 PMCID | 2025-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.Lancet Respir Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39581197无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy.Int J Clin Oncol | PMID 39585516无 PMCID | 2025-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39602678无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.Br J Psychiatry | PMID 39618237无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetic/Pharmacodynamic Modeling of Efficacy and Hypoglycemia Rate When Switching From Once-Daily Basal Insulin to Once-Weekly Insulin Icodec Without or With a One-Time Additional Dose in Insulin-Experienced Individuals With Type 2 Diabetes.Endocr Pract | PMID 39631663无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet Gastroenterol Hepatol | PMID 39637881无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39642775无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.Int J Urol | PMID 39648954无 PMCID | 2025-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy of CycloMesh™+Ropivacaine in the treatment of uncomplicated inguinal hernia after the Lichtenstein procedure: Results of a prospective multicentric double-blind study.J Visc Surg | PMID 39674692无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults with Crohn's Disease.Adv Ther | PMID 39692838PMC11787167 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reduction of postoperative pain and opioid consumption by VVZ-149, first-in-class analgesic molecule: A confirmatory phase 3 trial of laparoscopic colectomy.J Clin Anesth | PMID 39705738无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.Transfusion | PMID 39719927PMC11826292 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.Aliment Pharmacol Ther | PMID 39744921PMC11754939 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of SHR8554 on postoperative pain in subjects with moderate to severe acute pain following orthopedic surgery: A multicenter, randomized, double-blind, dose-explored, active-controlled, phase II/III clinical trial.Pharmacol Res | PMID 39755132无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nonopioid vs opioid analgesics after impacted third-molar extractions: The Opioid Analgesic Reduction Study randomized clinical trial.J Am Dent Assoc | PMID 39755971无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.Nat Med | PMID 39762418无 PMCID | 2025-Feb | 0.90 | The record describes a randomized phase 2 trial with a primary endpoint of pathological complete response (pCR), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis. The publication types include 'Clinical Trial, Phase II' and 'Clinical Trial, Phase III', but the abstract explicitly states it is a 'phase 2, randomized trial' with results. Phase 3 trials are only warranted, not presented. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria. | 待处理 |
| Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.Nat Med | PMID 39775042无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease.Stroke | PMID 39781748无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiotherapy Quality Assurance in the SCOPE2 Trial: What Lessons can be Learned for the Next UK Trial in Oesophageal Cancer?Clin Oncol (R Coll Radiol) | PMID 39799639无 PMCID | 2025-Feb | 0.90 | The record describes a quality assurance sub-study of a definitive oncology RCT (SCOPE2), but it does not report any survival, progression, recurrence, or other efficacy outcomes eligible for KM digitization. | 待处理 |
| Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.Lancet Haematol | PMID 39799953无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.Maturitas | PMID 39809112无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Population exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata.CPT Pharmacometrics Syst Pharmacol | PMID 39812118PMC11812936 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial.Lancet Diabetes Endocrinol | PMID 39818225无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.J Cachexia Sarcopenia Muscle | PMID 39825571PMC11788588 | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.Lancet HIV | PMID 39832519PMC11890582 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.Nat Med已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:森林图/亚组分析图;Fig. 3:AI 判定为 other;Extended Data Fig. 1:AI 判定为 forest plot;Extended Data Fig. 2:AI 判定为 flow diagram。 | PMID 39838117PMC11835712 | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.Nat Med | PMID 39838118PMC11835735 | 2025-Feb | 0.85 | The record is a Phase III randomized trial of a drug intervention in oncology with an original primary result. However, it does not meet the specific inclusion requirement of having a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The reported primary endpoint is pathological complete response (pCR), which is not a time-to-event endpoint. | 待处理 |
| Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy.Mult Scler Relat Disord | PMID 39847856无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial.Lancet Oncol | PMID 39848272无 PMCID | 2025-Feb | 0.95 | Eligible oncology human Phase III randomized trial with OS as primary endpoint and original results, but excluded because the intervention is a procedural (thermal ablation vs. surgical resection) and not a drug-containing regimen, as required. | 待处理 |
| Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.Gynecol Oncol | PMID 39854806PMC11929956 | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.Lancet Neurol | PMID 39862879无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.Lancet Neurol | PMID 39862880无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of Reperfusion Efficacy of Altelyse Versus Actilyse in Patients with Acute Myocardial Infarction: A Phase 3, Randomized, Double-Blinded, Non-inferiority Clinical Trial.Clin Drug Investig | PMID 39873854无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial.J Infect | PMID 39874991无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of tamoxifen in non-ambulant patients with Duchenne muscular dystrophy: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (TAMDMD Group B).Neuromuscul Disord | PMID 39879732无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39884222无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.Lancet Glob Health | PMID 39890232PMC11783036 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction: A Patient-Level Analysis of DAPA-HF and DELIVER.JACC Heart Fail | PMID 39909641无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39914418无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39914419无 PMCID | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.Ann Rheum Dis | PMID 39919893无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.ESMO Open | PMID 39921934PMC11850755 | 2025-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 部分完成 |
| Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.Circ Cardiovasc Interv | PMID 39965044无 PMCID | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.Clin Transl Sci | PMID 39980062PMC11842220 | 2025-Feb | 0.95 | The study is a Phase III randomized trial of imetelstat in myelodysplastic syndromes, but the report is a translational/safety analysis focused on proarrhythmic potential and QTc prolongation. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier curves or hazard ratios. The primary outcome described is the concentration-QTc relationship, which is a safety endpoint. | 待处理 |
| Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.J Cachexia Sarcopenia Muscle | PMID 39992021PMC11848863 | 2025-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.Eur Respir J | PMID 39467609PMC11799883 | 2025-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |